
The European Commission has approved daraxonrasib (RASONQUE®), the first broad RAS-targeted therapy for metastatic pancreatic cancer An important milestone for patients with pancreatic adenocarcinoma 💜 A promising step forward! #PancreaticCancer @RevMedicines























































